http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106928309-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J71-0005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J71-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 |
| filingDate | 2017-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106928309-B |
| titleOfInvention | A kind of spirosterine alkaloid glycoside alkaloid and its preparation method and use |
| abstract | The invention provides a spirosteroid alkaloid glycoside alkaloid (3β, 22α, 25R)-spirosteroid alk-5-alkenyl-3-O-β-D-glucopyranosyl-(1→2) -O-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside and preparation method and use thereof , human large cell lung cancer cells H460 and human lung squamous cell carcinoma cells SK-MES-1 have inhibitory effects, and the half-inhibitory concentration of A549 cells is 61.53 μg/ml, and the half-inhibitory concentration of H460 cells is 159.11 μg/ml. The half inhibitory concentration of SK-MES-1 cells is 81.64 μg/ml, it can be seen that the (3β, 22α, 25R)-spirosteroid alkane-5-alkenyl-3-O-β-D-pyran prepared by the present invention Glucosyl-(1→2)-O-β-D-glucopyranosyl-(1→4)-β-D-galactopyranoside and its preparation can be used for the treatment of non-small cell lung cancer. |
| priorityDate | 2017-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 58.